Immunology

Insights From Cencora's Dr Lakesha Farmer: Innovative Biosimilar Adoption Strategies

May 26th 2024

By Skylar Jeremias

Lakesha Farmer, PharmD, MBA, from Cencora discusses innovative pricing and reimbursement models incentivizing biosimilar adoption and competitiveness, including dual pricing strategies and the Mark Cuban Cost Plus Program, while highlighting potential impacts on patient assistance programs.

Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report

May 19th 2024

By Skylar Jeremias

Podcast

The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.

Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings

May 16th 2024

By Skylar Jeremias

Article

Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states, as well as cost savings.

Review: Product Attributes Relevant to Injection-Site Pain, Adalimumab Treatment

May 4th 2024

By Deana Ferreri, PhD

Article

A review article summarizes the product attributes of reference and biosimilar adalimumab products, such as formulation with or without citrate, delivery volume, and needle gauge, relevant to patients’ experience of injection-site pain.

FDA Approves High-Concentration Cyltezo

May 1st 2024

By Skylar Jeremias

Article

The FDA approved a high-concentration, citrate-free version of Boehringer Ingelheim’s Cyltezo (adalimumab-adbm), making it the second high-concentration adalimumab biosimilar to have an interchangeability designation.

Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar

April 29th 2024

By Skylar Jeremias

Article

The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.

The Totality of Evidence Supporting the Approval of Adalimumab Biosimilar GP2017

April 27th 2024

By Deana Ferreri, PhD

Article

A review article summarized the totality of evidence supporting the approval of the adalimumab biosimilar GP2017 (Hyrimoz; Sandoz) in the United States and Europe.

Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch

April 20th 2024

By Deana Ferreri, PhD

Article

In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.

Julie Reed: Why 2024 Is Important for Biosimilars

April 17th 2024

By Skylar Jeremias

Article

Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.

Fresenius Kabi's Tocilizumab Biosimilar, Tyenne, Launches in US Market

April 16th 2024

By Rose McNulty

Article

Tyenne (tocilizumab-aazg) was the second tocilizumab biosimilar to be FDA approved, but it is the first to launch in the US.